{"id":63562,"date":"2018-11-28T00:00:00","date_gmt":"2018-11-28T06:00:00","guid":{"rendered":"https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/"},"modified":"2018-11-28T00:00:00","modified_gmt":"2018-11-28T06:00:00","slug":"internal-medicine-research-and-non-research-awards-third-quarter-2018","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/","title":{"rendered":"Internal Medicine Research and Non-Research Awards – Third Quarter 2018"},"content":{"rendered":"

Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost<\/strong>
\n 
\nGoldsweig, Andrew Michael, <\/strong>
\nNational Cardiogenic Shock Initiative (NCSI), 22071, Henry Ford Health System, 06\/15\/18-06\/14\/19, $12,556 , $2,485 , $15,041
\nThe Randomized And Controlled Noninferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil Drug-Coated Balloon iN the Treatment of Subjects with Stenotic Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT® Admiral®…, 21922, SurModics, Inc., 07\/06\/18-07\/05\/20, $0 , $48,638 , $48,638
\nThe Randomized And Controlled Noninferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil Drug-Coated Balloon iN the Treatment of Subjects with Stenotic Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT® Admiral®…, 21922, SurModics, Inc., 07\/06\/18-07\/05\/20, $252,425 , $16,213 , $268,638
\nSubtotal Awards: 3,  Subtotals, $264,981 , $67,336 , $332,317
\n 
\nPavlides, Gregory S,<\/strong>
\nA Post Approval Study of the Medtronic Resolute Onyx TM Zotarolimus-eluting Coronary Stent System, 21307, Medtronic, Inc., 07\/13\/18-07\/12\/20, $25,130 , $5,754 , $30,884
\nSubtotal Awards: 1,   Subtotals, $25,130 , $5,754 , $30,884
\n 
\nPorter, Thomas Richard, <\/strong>
\nRegadenoson Real Time Perfusion Imaging Trial – Optison [regadenoson from Astellas\/ Optison from GE] – interventional, 15908, Astellas Pharma Global Development, Inc., 07\/31\/12-09\/30\/15, $2,500 , $0 , $2,500
\nSubtotal Awards: 1,   Subtotals, $2,500 , $0 , $2,500
\n 
\nWindle, John Robert,<\/strong>
\nOptimizing the Electronic Health Record for Cardiac Care, 16308, DHHS\/AHRQ, 09\/01\/18-08\/31\/19, $367,600 , $132,398 , $499,998
\nOptimizing the Electronic Health Record for Cardiac Care, 16308, DHHS\/AHRQ, 09\/01\/18-08\/31\/19, $367,600 , $132,398 , $499,998
\nSubtotal Awards: 2, Subtotals, $735,200 , $264,796 , $999,996
\n 
\nZolty, Ronald, <\/strong>
\nA Double-blind, Randomized, Placebo-Controlled Study of Levosimendan in Patients with Left Ventricular Systopic Dysfunction Undergoing Cardiiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS), 19551, Tenax Therapeutics, Inc., 04\/13\/16-04\/12\/17, $0 , ($1,686), ($1,686)
\nA Double-blind, Randomized, Placebo-Controlled Study of Levosimendan in Patients with Left Ventricular Systopic Dysfunction Undergoing Cardiiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS), 19551, Tenax Therapeutics, Inc., 04\/13\/16-04\/12\/17, ($33,053), ($1,921), ($34,974)
\nSubtotal Awards: 2,   Subtotals, ($33,053), ($3,607), ($36,660)
\n 
\nBennett, Robert G, <\/strong>
\nA Novel Therapeutic for Liver Fibrosis, 15889, Angion Biomedica Corp., 05\/01\/13-10\/31\/14, ($39,821), $0 , ($39,821)
\nSubtotal Awards: 1 Subtotals, ($39,821), $0 , ($39,821)
\n 
\nDesouza, Cyrus Victor, <\/strong>
\nA Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes Diabetes (SUSTAIN), 16898, Novo Nordisk Pharmaceuticals, Inc., 04\/12\/13-04\/11\/17, ($42,274), $0 , ($42,274)
\nNEBRA ICA for James Pfeifer, 17306, Nebraska Educational Biomedical Research Association, 10\/01\/13-09\/30\/14, ($17,131), $0 , ($17,131)
\nNEBRA ICA for Rob Heineman, 17307, Nebraska Educational Biomedical Research Association, 06\/01\/15-07\/31\/15, ($33,772), $0 , ($33,772)
\nNEBRA ICA for Grace Lord., 19521, Nebraska Educational Biomedical Research Association, 07\/01\/16-06\/30\/17, ($24,234), $0 , ($24,234)
\nNEBRA ICA for Tara Asgarpoor, 19614, Nebraska Educational Biomedical Research Association, 07\/01\/16-06\/30\/17, ($18,126), $0 , ($18,126)
\nICA for Swetha Mereddy, 20309, Nebraska Educational Biomedical Research Association, 09\/01\/16-06\/30\/17, ($60,480), $0 , ($60,480)
\nVitamin D to prevent type 2 diabetes (D2d study), 15982, Tufts University, 06\/25\/18-01\/31\/19, $115,334 , $57,687 , $173,021
\nICA for Megan Severson, 21276, Nebraska Educational Biomedical Research Association, 07\/01\/18-06\/30\/19, $10,867 , $0 , $10,867
\nNEBRA ICA for Jenna Eggert, 19340, Nebraska Educational Biomedical Research Association, 07\/01\/18-06\/30\/19, $33,823 , $0 , $33,823
\nNEBRA ICA for Lisa Kuechenmeister, 19819, Nebraska Educational Biomedical Research Association, 07\/01\/18-06\/30\/19, $54,355 , $0 , $54,355
\nNERBA ICA for Curtis Perriotte-Olson, 18695, Nebraska Educational Biomedical Research Association, 07\/01\/18-06\/30\/19, $42,558 , $0 , $42,558
\nA Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal…, 21798, Sanofi U.S. Services, Inc., 08\/15\/18-08\/14\/25, $0 , $56,542 , $56,542
\nA Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal…, 21798, Sanofi U.S. Services, Inc., 08\/15\/18-08\/14\/25, $290,959 , $18,847 , $309,806
\nICA for Katelyn Kelley, 22398, Nebraska Educational Biomedical Research Association, 08\/21\/18-06\/30\/19, $7,069 , $0 , $7,069
\nSubtotal Awards: 14,  ,  , Subtotals, $358,948 , $133,076 , $492,024
\n 
\nShivaswamy, Vijay, <\/strong>
\nPhase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation of the Efficacy, Safety, and Tolerabity of PF-04950615, in Reduciing the Occurrence of Major Cardiovascular Events in Subjects at High and Very High Risk (SPIRE), 17671, Pfizer, Inc., 06\/24\/14-06\/30\/17, ($196,043), $0 , ($196,043)
\nPHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS – SPIRE (B1481038), 18142, Pfizer, Inc., 02\/10\/15-06\/30\/17, ($188,742), $0 , ($188,742)
\nICA for Renee Tillson, 22444, Nebraska Educational Biomedical Research Association, 09\/01\/18-08\/31\/19, $42,097 , $0 , $42,097
\nSubtotal Awards: 3,  ,  , Subtotals, ($342,688), $0 , ($342,688)
\n 
\nViswanathan, Saraswathi, <\/strong>
\nThe Effectiveness of NanoSOD in Ameliorating Ethanol-induced Liver Injury in Obesity, 20754, DHHS\/NIH\/NIAAA, 09\/01\/18-08\/31\/19, $118,750 , $30,875 , $149,625
\nSubtotal Awards: 1, Subtotals, $118,750 , $30,875 , $149,625
\n 
\nCasey, Carol A, <\/strong>
\nAltered Lipid Droplet Trafficking Role in Alcoholic Fatty Liver Disease, 19689, DHHS\/NIH\/NIAAA, 05\/01\/18-04\/30\/19, $520,046 , $52,000 , $572,046
\nCOBRE Nebraska Center for the Prevention of Obesity Diseases through Dietary Molecules, 18447, University of Nebraska – Lincoln, 06\/01\/18-05\/31\/19, $9,380 , $4,737 , $14,117
\nSubtotal Awards: 2, Subtotals, $529,426 , $56,737 , $586,163
\n 
\nGanesan, Murali, <\/strong>
\nEthanol suppresses HBV peptide-MHC class I presentation on hepatocytes, 21437, DHHS\/NIH\/NIAAA, 08\/01\/18-07\/31\/19, $126,583 , $10,127 , $136,710
\nSubtotal Awards: 1, Subtotals, $126,583 , $10,127 , $136,710
\n 
\nMccashland, Timothy Mark, <\/strong>
\nA Multicenter, Randomized, Open-label, Active-controlled, Trial to Evaluate the Safety and Efficacy of Rifaximin 550 MG with and without Lactulose in Subjects History of Recurrent Overt Hepatic Encephalopathy, 16872, Salix Pharmacueticals, Inc., 07\/15\/13-07\/14\/15, ($41,769), $0 , ($41,769)
\nSubtotal Awards: 1, Subtotals, ($41,769), $0 , ($41,769)
\n 
\nSingh, Shailender, <\/strong>
\nPancreatic Cystic Reference Set, 17748, University of Pittsburgh, 07\/01\/15-06\/30\/16, ($8,880), $0 , ($8,880)
\nSubtotal Awards: 1,  Subtotals, ($8,880), $0 , ($8,880)
\n 
\nShiffermiller, Jason Floyd, <\/strong>
\nMidtown Multimorbidity Project, 16709, Blue Cross\/Blue Shield, 01\/01\/14-06\/30\/15, ($49,331), $0 , ($49,331)
\nSubtotal Awards: 1, Subtotals, ($49,331), $0 , ($49,331)
\n 
\nHannan, Jeannine M, <\/strong>
\nEngage Wellness Diabetes Program, 20048, Douglas County Health Department, 09\/30\/16-09\/28\/17, ($2,379), $0 , ($2,379)
\nSubtotal Awards: 1,  Subtotals, ($2,379), $0 , ($2,379)
\n 
\nPotter, Jane Frances, <\/strong>
\nPhysician Training in Interprofessional Care, 14429, Donald W. Reynolds Foundation, 01\/01\/15-06\/30\/15, ($71,978), $0 , ($71,978)
\nSubtotal Awards: 1,  Subtotals, ($71,978), $0 , ($71,978)
\n 
\nBares, Sara, <\/strong>
\nAn evaluation of bone mineral density in HIV-1-infected adult subjects switching from a tenofovir-containing antiretroviral therapy regimen to a dolutegravir plus rilpivirine regimen (DEXA Study), 19019, GlaxoSmithKline, 07\/24\/15-06\/17\/18, $0 , ($309), ($309)
\nAn evaluation of bone mineral density in HIV-1-infected adult subjects switching from a tenofovir-containing antiretroviral therapy regimen to a dolutegravir plus rilpivirine regimen (DEXA Study), 19019, GlaxoSmithKline, 07\/24\/15-06\/17\/18, ($1,586), ($103), ($1,689)
\nSubtotal Awards: 2,  Subtotals, ($1,586), ($412), ($1,998)
\n 
\nFlorescu, Diana Florentina, <\/strong>
\nComparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects Two – Seventeen Years of Age With Bacteremia caused by Staphylococcus aureus, 16595, Cubist Pharmaceuticals, Inc, 02\/06\/13-06\/30\/17, $4,581 , $0 , $4,581
\nSubtotal Awards: 1, Subtotals, $4,581 , $0 , $4,581
\n 
\nFreifeld, Alison Gail, <\/strong>
\nA Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic…, 16662, Optimer Pharmaceuticals, Inc., 04\/30\/13-04\/30\/15, ($249,473), $0 , ($249,473)
\nSubtotal Awards: 1, Subtotals, ($249,473), $0 , ($249,473)
\n 
\nHewlett, Angela L, <\/strong>
\nMicrobial Field Forensics, 17364, National Strategic Research Institute, 05\/06\/13-04\/21\/14, ($2,735), $0 , ($2,735)
\nSubtotal Awards: 1, Subtotals, ($2,735), $0 , ($2,735)
\n 
\nKalil, Andre C, <\/strong>
\nEvaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock (EUPHRATES), 14659, Spectral Diagnostics Inc., 12\/13\/10-03\/31\/16, ($273,170), $0 , ($273,170)
\nProfessional Services Agreement: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered via the Investigational eFlow Inline System in Mechanically Ventilated Patients with Gram-neg, 17729, Rhode Island Hospital, 08\/01\/15-04\/30\/16, $3,233 , $0 , $3,233
\nSubtotal Awards: 2, Subtotals, ($269,937), $0 , ($269,937)
\n 
\nSandkovsky, Uriel Sebastian, <\/strong>
\nING114467: A Phase III, Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 plus Abacavir\/lamivudine Fixed-dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1…, 14952, GlaxoSmithKline, 02\/01\/11-03\/31\/15, ($42,002), $0 , ($42,002)
\nSubtotal Awards: 1, Subtotals, ($42,002), $0 , ($42,002)
\n 
\nSwindells, Susan, <\/strong>
\nA Multicenter, Randomized, Double-blind, Comparative Trial of Maraviroc + Darunavir\/Ritonavir Versus Emtricitabine\/Tenofovir + Darunavir\/Ritonavir for the Treatment of Antiretroviral-Naïve HIV-Infected Patients with CCR5-TROPIC HIV-1, 15349, ViiV Healthcare Limited, 09\/16\/11-09\/15\/14, ($7,524), $0 , ($7,524)
\nLong-term Follow-up of Study Participants from GlaxoSmithKline (GSK) Biologicals-sponsored Clinical Trials Evaluating Human Immunodeficiency Virus Vaccine [F4co (p24-RT-Nef-p17)\/AS01B Vaccine] (732462) for Therapeutic Use, 15849, GlaxoSmithKline, 07\/27\/12-06\/30\/16, ($1,504), $0 , ($1,504)
\nAIDS Clinical Trials Group Network (ACTG), 16481, Brigham & Women's Hospital, 12\/01\/17-11\/30\/18, $33,619 , $16,949 , $50,568
\nAIDS Drug Assistance Program [ADAP] Ryan White Title II Program (Part B), 21175, NE DHHS, 04\/01\/18-03\/31\/19, $1,318,297 , $0 , $1,318,297
\nUnderstanding the dynamics of switching to long-acting, injectable ART from fixed dose oral combination therapies among PLHIV in the U.S., Spain, and Argentina, 21907, American University, 05\/15\/18-05\/14\/19, $3,968 , $1,032 , $5,000
\nA Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 infected Adults who are Virologically Suppressed and Part, 22074, GlaxoSmithKline, 08\/15\/18-08\/14\/20, $0 , $3,649 , $3,649
\nA Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 infected Adults who are Virologically Suppressed and Part, 22074, GlaxoSmithKline, 08\/15\/18-08\/14\/20, $19,711 , $1,216 , $20,927
\nSubtotal Awards: 7,  Subtotals, $1,366,567 , $22,846 , $1,389,413
\n 
\nVanschooneveld, Trevor Craig, <\/strong>
\nA Randomized, Double-blinded, Active-controlled Study of CB-183,315 in Patients with Clostridium Difficile Associated Diarrhea, 16907, Cubist Pharmaceuticals, Inc, 05\/21\/13-03\/31\/16, ($60,116), $0 , ($60,116)
\nSubtotal Awards: 1,  Subtotals, ($60,116), $0 , ($60,116)
\n 
\nLangewisch, Eric D, <\/strong>
\nInformed Consent To Participate In The Evaluation Of Patient Outcomes From The Kidney Allograft Outcomes Allosure Registry (KOAR), 21638, CareDx, Inc, 05\/23\/18-05\/22\/22, $74,958 , $19,229 , $94,187
\nSubtotal Awards: 1, Subtotals, $74,958 , $19,229 , $94,187
\n 
\nAl-Kadhimi, Zaid S, <\/strong>
\nA Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Grate-versus-Host-Disease in Adult and Pediatric Patients After Allogenic Hematopoietic Stem Cell T, 21811, Jazz Pharmaceuticals, 07\/19\/18-07\/18\/20, $0 , $35,392 , $35,392
\nA Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Grate-versus-Host-Disease in Adult and Pediatric Patients After Allogenic Hematopoietic Stem Cell T, 21811, Jazz Pharmaceuticals, 07\/19\/18-07\/18\/20, $182,499 , $11,798 , $194,297
\nSubtotal Awards: 2,  Subtotals, $182,499 , $47,190 , $229,689
\n 
\nBhatt, Vijaya R, <\/strong>
\nGRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease, 21591, Incyte Corporation, 07\/10\/18-07\/08\/20, $0 , $36,716 , $36,716
\nGRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease, 21591, Incyte Corporation, 07\/10\/18-07\/08\/20, $191,289 , $12,239 , $203,528
\nA Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML, 21534, Tolero Pharmaceuticals Inc., 08\/01\/18-07\/31\/20, $0 , $19,497 , $19,497
\nA Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML, 21534, Tolero Pharmaceuticals Inc., 08\/01\/18-07\/31\/20, $102,987 , $6,500 , $109,487
\nA Single Arm, Open Label, Phase II Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease after Failure of Systemic Glucocorticoids, 21367, Incyte Corporation, 08\/30\/18-08\/29\/20, $0 , $65,904 , $65,904
\nA Single Arm, Open Label, Phase II Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease after Failure of Systemic Glucocorticoids, 21367, Incyte Corporation, 08\/30\/18-08\/29\/20, $340,971 , $21,968 , $362,939
\nSubtotal Awards: 6, Subtotals, $635,247 , $162,824 , $798,071
\n 
\nBierman, Philip J, <\/strong>
\nA Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies, 16606, OncoMed Pharmaceuticals, Inc., 02\/13\/13-05\/31\/17, ($119,576), $0 , ($119,576)
\nSubtotal Awards: 1, Subtotals, ($119,576), $0 , ($119,576)
\n 
\nErnani, Vinicius, <\/strong>
\nA Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +\/-Pembrolizumab (MK-3475) as Neoadjuvant\/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671), 21738, Merck Sharp & Dohme Corp., 07\/19\/18-07\/18\/20, $0 , $31,492 , $31,492
\nA Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +\/-Pembrolizumab (MK-3475) as Neoadjuvant\/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671), 21738, Merck Sharp & Dohme Corp., 07\/19\/18-07\/18\/20, $162,498 , $10,497 , $172,995
\nSubtotal Awards: 2, Subtotals, $162,498 , $41,989 , $204,487
\n 
\nFaber, Edward Anthony, <\/strong>
\nA Phase III Randomized, Multicenter Trial Testing Whether Exercise and\/or Stress Management Improves Functional Status and Symptoms of Autologous and Allogeneic Recipients, 15376, National Marrow Donor Program, 05\/29\/11-05\/31\/17, $54,800 , $0 , $54,800
\nSubtotal Awards: 1, Subtotals, $54,800 , $0 , $54,800
\n 
\nGrem, Jean Linette, <\/strong>
\nLaboratory Studies for ECOG Protocol E4203, 11306, Frontier Science & Technology Research Foundation, Inc., 08\/07\/06-05\/31\/16, ($31,512), $0 , ($31,512)
\nPhase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expresssion in Previously Untreated Patients with Metastatic Colorectal Cancer, 11254, Eastern Cooperative Oncology Group, 08\/07\/06-05\/31\/16, $3,475 , $0 , $3,475
\nSubtotal Awards: 2, Subtotals, ($28,037), $0, ($28,037)
\n 
\nHolstein, Sarah A, <\/strong>
\nInvestigation of the biodistribution of novel multiple myeloma drugs, 21596, NE DHHS – LB506, 07\/01\/18-06\/30\/19, $50,000 , $0 , $50,000
\nA Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma, 21547, JANSSEN R&D, LLC, 08\/01\/18-07\/31\/20, $0 , $29,255 , $29,255
\nA Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma, 21547, JANSSEN R&D, LLC, 08\/01\/18-07\/31\/20, $153,025 , $9,752 , $162,777
\nA Phase 1\/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma, 21717, AbbVie, Inc., 09\/07\/18-09\/06\/20, $0 , $50,668 , $50,668
\nA Phase 1\/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma, 21717, AbbVie, Inc., 09\/07\/18-09\/06\/20, $260,837 , $16,890 , $277,727
\nSubtotal Awards: 5, Subtotals, $463,862 , $106,565 , $570,427
\n 
\nLunning, Matthew A, <\/strong>
\nA Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chem, 16013, Talon Therapeutics, Inc., 09\/05\/12-12\/31\/15, ($55,124), $0 , ($55,124)
\nA Phase Ib\/IIa Study of Combination Therapy with Carfilzomib, Romidepsin, Lenalidomide in Patients with Relapsed or Refractory B- and T-cell Lymphomas, 18928, Memorial Sloan-Kettering Cancer Center, 04\/08\/16-02\/28\/18, ($12,935), $0 , ($12,935)
\nA Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL),, 19944, Memorial Sloan-Kettering Cancer Center, 06\/13\/18-06\/12\/20, $0 , $2,987 , $2,987
\nA Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL),, 19944, Memorial Sloan-Kettering Cancer Center, 06\/13\/18-06\/12\/20, $18,317 , $995 , $19,312
\nSubtotal Awards: 4, Subtotals, ($49,742), $3,982 , ($45,760)
\n 
\nManess Harris, Lori J, <\/strong>
\nA Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), 15058, Novartis Pharmaceuticals Corporation, 04\/14\/11-12\/31\/15, ($18,053), $0 , ($18,053)
\nPivotal Study Data Collection: Defibrotide for Severe Veno-Occlusive Disease: A Historically Controlled Multi-Center Phase 3 Study for Safety and Efficacy, 16611, Gentium S.p.A., 12\/19\/12-05\/31\/17, $12,494 , $0 , $12,494
\nAn Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigators Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL), 16990, Pfizer, Inc., 10\/10\/13-02\/28\/16, ($84,609), $0 , ($84,609)
\nInternet Studies to Enhance Long Term Survivorship after Hematologic Malignancy, 14835, Fred Hutchinson Cancer Research Center, 08\/01\/14-07\/31\/15, $14,800 , $0 , $14,800
\nA Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia, 21465, Nohla Therapeutics, 06\/11\/18-06\/10\/20, $0 , $28,659 , $28,659
\nA Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia, 21465, Nohla Therapeutics, 06\/11\/18-06\/10\/20, $149,970 , $9,553 , $159,523
\nSubtotal Awards: 6, Subtotals, $74,602 , $38,212 , $112,814
\n 
\nReed, Elizabeth Cecile, <\/strong>
\nA Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Advanced or Metastatic Breast Cancer, 14254, Novartis Pharmaceuticals Corporation, 08\/03\/10-01\/31\/16, ($27,182), $0 , ($27,182)
\nA Randomized Phase III, Double-Blind, Placebo-Controlled, Multicenter Trial of Daily Everolimus in Combination with Trastuzumab and Vinorelbine in Pretreated Women with HER2\/neu Over-expressing Locally Advanced or Metastatic Breast Cancer, 14255, Novartis Pharmaceuticals Corporation, 08\/04\/10-12\/31\/15, ($33,904), $0 , ($33,904)
\nSubtotal Awards: 2, Subtotals, ($61,086), $0 , ($61,086)
\n 
\nSchwarz, James Kendal, <\/strong>
\nPhase 3 Randomized, Double-blind, Controlled trial of Cabozantinib (XL184) vs. Mitoxtanrone plus Prednisone in Men with Previously Treated Symptomatic Castration-resistant Prostate Cancer, 16687, Exelixis, Inc., 02\/08\/13-02\/07\/16, ($89,412), $0 , ($89,412)
\nSubtotal Awards: 1, Subtotals, ($89,412), $0 , ($89,412)
\n 
\nVose, Julie M, <\/strong>
\nA Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma who Progress after Bortezomib Therapy, 16502, JANSSEN R&D, LLC, 01\/25\/13-02\/28\/16, ($11,879), $0 , ($11,879)
\nAn Open-label Phase II Study of BKM120 in Patients with Relapsed and Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma, 16897, Novartis Pharma, Inc., 04\/15\/13-04\/30\/16, ($20,330), $0 , ($20,330)
\nNebraska\/Kansas Blood and Marrow Transplant Research Network, 14897, DHHS\/NIH\/NHLBI, 07\/01\/16-06\/30\/17, ($94,045), $0 , ($94,045)
\nSubtotal Awards: 3, Subtotals, ($126,254), $0 , ($126,254)
\n 
\nBailey, Kristina Lynn, <\/strong>
\nBiphasic Alcohol Regulation of TLR2 in Airway Epithelium, 13848, DHHS\/NIH\/NIAAA, 03\/01\/14-02\/28\/16, $1,943 , $0 , $1,943
\nSubtotal Awards: 1, Subtotals, $1,943 , $0 , $1,943
\n 
\nDickinson, John David, <\/strong>
\nAutophagy regulates airway epithelial cell mucin secretion, 19322, DHHS\/NIH\/NHLBI, 09\/01\/18-08\/31\/19, $148,000 , $11,840 , $159,840
\nSubtotal Awards: 1, Subtotals, $148,000 , $11,840 , $159,840
\n 
\nGrant, Kathleen M, <\/strong>
\nIntensive Referral to Al-Anon: Benefits to Concerned Others and Their Drinkers, 20806, Palo Alto Institute for Reseach and Education, Inc., 07\/01\/18-06\/30\/19, $81,954 , $21,308 , $103,262
\nSubtotal Awards: 1, Subtotals, $81,954 , $21,308 , $103,262
\n 
\nHarrington, John J, <\/strong>
\nTailored treatment to enhance risk perception in sleep apnea – subcontract with National Jewish Health, 18868, National Jewish Research, 04\/01\/18-03\/31\/19, $14,601 , $7,374 , $21,975
\nSubtotal Awards: 1, Subtotals, $14,601 , $7,374 , $21,975
\n 
\nMurphy, P. James James, <\/strong>
\nCFF Center Adult Program, 17416, Cystic Fibrosis Foundation, 07\/01\/18-06\/30\/19, $105,975 , $0 , $105,975
\nA Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F\/MF), 21649, Vertex Pharmaceuticals Incorporated, 07\/11\/18-07\/10\/20, $0 , $13,545 , $13,545
\nA Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F\/MF), 21649, Vertex Pharmaceuticals Incorporated, 07\/11\/18-07\/10\/20, $70,464 , $4,516 , $74,980
\n2018 Proposal for Mental Health Coordinator, 22314, Cystic Fibrosis Foundation, 09\/01\/18-08\/31\/19, $45,740 , $4,000 , $49,740
\nSubtotal Awards: 4, Subtotals, $222,179 , $22,061 , $244,240
\n 
\nNordgren, Tara Marie, <\/strong>
\nThe role of omega-3 fatty acids and bioactive lipid signaling in airway inflammation and resolution following organic dust exposures, 18609, DHHS\/NIH\/NIEHS, 07\/01\/16-06\/30\/17, ($1,276), $0 , ($1,276)
\nSubtotal Awards: 1, Subtotals, ($1,276), $0 , ($1,276)
\n 
\nRennard, Stephen Israel, <\/strong>
\nA Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate\/ Vilanterol Inhalation Powder 100\/25mcg with Placebo on Survival in Subjects with Moderate Chronic Obstructive Pulmonary Disease (COPD) and…, 15344, GlaxoSmithKline, 12\/07\/11-08\/31\/15, $29,647 , $0 , $29,647
\nA Randomized, Double Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD…, 17224, Pearl Therapeutics, Inc., 08\/08\/13-12\/31\/14, $23,620 , $0 , $23,620
\nDesign and Testing of Practical Tools to Identify Individuals at High Risk for COPD, 15490, Weill Medical College of Cornell University, 08\/01\/15-07\/31\/16, $18,218 , $0 , $18,218
\nSubtotal Awards: 3, Subtotals, $71,485 , $0 , $71,485
\n 
\nSchneberger, David, <\/strong>
\nEffect of Elevated Carbon Dioxide on Lung Inflammation in Barn Dust-Instilled Mice, 17280, University of Iowa, 09\/30\/13-09\/29\/14, ($1,168), $0 , ($1,168)
\nSubtotal Awards: 1, Subtotals, ($1,168), $0 , ($1,168)
\n 
\nThompson, Austin Bassett, <\/strong>
\nRegistry to PROSPECTively Describe Use of Epoprostenol for Injection (RTS Epoprostenol) in Patients with Pulmonary Arterial Hypertension (PROSPECT Registry), 14921, Actelion Pharmaceuticals US, Inc., 08\/19\/11-06\/30\/14, ($22,272), $0 , ($22,272)
\nPIPF-016: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis, 15374, InterMune, Inc., 11\/09\/11-12\/31\/13, ($15,960), $0 , ($15,960)
\nAn Open-Label Extension Study of UT-15C in Subjects with Pulmonary Arterial Hypertension – A Long-Term Follow-Up to Protocol TDE-PH-310, 16236, United Therapeutics Corporation, 06\/10\/13-06\/09\/14, ($44,851), $0 , ($44,851)
\nA Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Event Driven Study to Compare the Time to First Clinical Worsening in Subjects with Pulmonary Arterial Hypertension Receiving UT-15C in Combination with a PDE5-I…, 16225, United Therapeutics Corporation, 06\/10\/13-06\/09\/14, ($82,060), $0 , ($82,060)
\nA Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients with Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument (SYMPHONY – ACT-064992), 17153, Actelion Pharmaceuticals US, Inc., 02\/11\/14-02\/10\/15, ($12,869), $0 , ($12,869)
\nSubtotal Awards: 5, Subtotals, ($178,012), $0 , ($178,012)
\n 
\nEngland, Bryant Robert, <\/strong>
\nScientist Development Award, 20145, Rheumatology Research Foundation, 07\/01\/18-06\/30\/19, $50,000 , $0 , $50,000
\nSubtotal Awards: 1, Subtotals, $50,000 , $0 , $50,000
\n 
\nKlassen, Lynell Warren, <\/strong>
\nUNMC Summer Undergraduate Alcohol Research Program, 15139, DHHS\/NIH\/NIAAA, 02\/01\/16-01\/31\/17, ($5,861), $0 , ($5,861)
\nSubtotal Awards: 1, Subtotals, ($5,861), $0 , ($5,861)
\n 
\nMikuls, Ted Richard, <\/strong>
\nA Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade with Tocilizumab (TCZ) in Comparison with Etanercept (ETA) on the Rate of Ischemic Cardiovascular Events in Patients with Moderate to Severe Rheumatoid Arthritis (RA), 15443, Genentech, Inc., 05\/09\/12-05\/08\/17, ($669,849), $0 , ($669,849)
\nSummer Undergraduate Alcohol Research Program, 19990, DHHS\/NIH\/NIAAA, 04\/01\/18-03\/31\/19, $5,762 , $461 , $6,223
\nResident Research Preceptorship, 22344, Rheumatology Research Foundation, 07\/01\/18-06\/30\/19, $14,995 , $0 , $14,995
\nSubtotal Awards: 3, Subtotals, ($649,092), $461 , ($648,631)
\n 
\nO'Dell, James Robert, <\/strong>
\nEvolving adaptive and effector mechanisms from Pre-RA through established disease, 18351, University of Colorado Denver, 09\/24\/14-05\/31\/15, ($2,274), $0 , ($2,274)
\nSubtotal Awards: 1, Subtotals, ($2,274), $0 , ($2,274)
\n 
\nThiele, Geoffrey Milton, <\/strong>
\nAlcohol Induces Muscle Autophagy by a Novel AMPK Independent PI3K Mediated Mechanism, 17144, Cleveland Clinic Foundation, 09\/25\/15-08\/31\/16, ($10,730), $0 , ($10,730)
\nSubtotal Awards: 1, Subtotals, ($10,730), $0 , ($10,730)
\n 
\nKessinger, Margaret Anne, <\/strong>
\nA Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous, NonSmall-Cell Lung Cancer (NSCLC), 14958, Daiichi Sankyo, Inc., 05\/06\/11-12\/31\/15, $25,268 , $0 , $25,268
\nSubtotal Awards: 1, Subtotals, $25,268 , $0 , $25,268
\n 
\n <\/p>\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"

Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost   Goldsweig, Andrew Michael, National Cardiogenic Shock Initiative (NCSI), 22071, Henry Ford Health System, 06\/15\/18-06\/14\/19, $12,556 , $2,485 , $15,041 The Randomized And Controlled Noninferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil Drug-Coated Balloon iN the Treatment of Subjects with Stenotic […]<\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-63562","post","type-post","status-publish","format-standard","hentry","category-uncategorized","department-internal-medicine-newsletter"],"yoast_head":"\nInternal Medicine Research and Non-Research Awards - Third Quarter 2018<\/title>\n<meta name=\"description\" content=\"Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost   Goldsweig, Andrew Michael, National Cardiogenic Shock Initiative\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Internal Medicine Research and Non-Research Awards - Third Quarter 2018\" \/>\n<meta property=\"og:description\" content=\"Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost   Goldsweig, Andrew Michael, National Cardiogenic Shock Initiative\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"Newsroom\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/unmcedu\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-28T06:00:00+00:00\" \/>\n<meta name=\"author\" content=\"Maria Daniels\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@unmc\" \/>\n<meta name=\"twitter:site\" content=\"@unmc\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maria Daniels\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2018\\\/11\\\/28\\\/internal-medicine-research-and-non-research-awards-third-quarter-2018\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2018\\\/11\\\/28\\\/internal-medicine-research-and-non-research-awards-third-quarter-2018\\\/\"},\"author\":{\"name\":\"Maria Daniels\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#\\\/schema\\\/person\\\/64f8bde080ce4f3e8d0f0663db14e4bc\"},\"headline\":\"Internal Medicine Research and Non-Research Awards – Third Quarter 2018\",\"datePublished\":\"2018-11-28T06:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2018\\\/11\\\/28\\\/internal-medicine-research-and-non-research-awards-third-quarter-2018\\\/\"},\"wordCount\":2992,\"publisher\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#organization\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2018\\\/11\\\/28\\\/internal-medicine-research-and-non-research-awards-third-quarter-2018\\\/\",\"url\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2018\\\/11\\\/28\\\/internal-medicine-research-and-non-research-awards-third-quarter-2018\\\/\",\"name\":\"Internal Medicine Research and Non-Research Awards - Third Quarter 2018\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#website\"},\"datePublished\":\"2018-11-28T06:00:00+00:00\",\"description\":\"Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost   Goldsweig, Andrew Michael, National Cardiogenic Shock Initiative\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2018\\\/11\\\/28\\\/internal-medicine-research-and-non-research-awards-third-quarter-2018\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2018\\\/11\\\/28\\\/internal-medicine-research-and-non-research-awards-third-quarter-2018\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2018\\\/11\\\/28\\\/internal-medicine-research-and-non-research-awards-third-quarter-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Internal Medicine Research and Non-Research Awards – Third Quarter 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#website\",\"url\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/\",\"name\":\"Newsroom\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#organization\",\"name\":\"University of Nebraska Medical Center\",\"url\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/overview-1.png\",\"contentUrl\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/overview-1.png\",\"width\":500,\"height\":153,\"caption\":\"University of Nebraska Medical Center\"},\"image\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/unmcedu\",\"https:\\\/\\\/x.com\\\/unmc\",\"https:\\\/\\\/instagram.com\\\/iamunmc\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/UNMCEDU\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#\\\/schema\\\/person\\\/64f8bde080ce4f3e8d0f0663db14e4bc\",\"name\":\"Maria Daniels\",\"url\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/author\\\/202cb962ac59075b964b07152d234b70\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Internal Medicine Research and Non-Research Awards - Third Quarter 2018","description":"Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost   Goldsweig, Andrew Michael, National Cardiogenic Shock Initiative","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/","og_locale":"en_US","og_type":"article","og_title":"Internal Medicine Research and Non-Research Awards - Third Quarter 2018","og_description":"Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost   Goldsweig, Andrew Michael, National Cardiogenic Shock Initiative","og_url":"https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/","og_site_name":"Newsroom","article_publisher":"https:\/\/www.facebook.com\/unmcedu","article_published_time":"2018-11-28T06:00:00+00:00","author":"Maria Daniels","twitter_card":"summary_large_image","twitter_creator":"@unmc","twitter_site":"@unmc","twitter_misc":{"Written by":"Maria Daniels","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/#article","isPartOf":{"@id":"https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/"},"author":{"name":"Maria Daniels","@id":"https:\/\/www.unmc.edu\/newsroom\/#\/schema\/person\/64f8bde080ce4f3e8d0f0663db14e4bc"},"headline":"Internal Medicine Research and Non-Research Awards – Third Quarter 2018","datePublished":"2018-11-28T06:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/"},"wordCount":2992,"publisher":{"@id":"https:\/\/www.unmc.edu\/newsroom\/#organization"},"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/","url":"https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/","name":"Internal Medicine Research and Non-Research Awards - Third Quarter 2018","isPartOf":{"@id":"https:\/\/www.unmc.edu\/newsroom\/#website"},"datePublished":"2018-11-28T06:00:00+00:00","description":"Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost   Goldsweig, Andrew Michael, National Cardiogenic Shock Initiative","breadcrumb":{"@id":"https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.unmc.edu\/newsroom\/2018\/11\/28\/internal-medicine-research-and-non-research-awards-third-quarter-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.unmc.edu\/newsroom\/"},{"@type":"ListItem","position":2,"name":"Internal Medicine Research and Non-Research Awards – Third Quarter 2018"}]},{"@type":"WebSite","@id":"https:\/\/www.unmc.edu\/newsroom\/#website","url":"https:\/\/www.unmc.edu\/newsroom\/","name":"Newsroom","description":"","publisher":{"@id":"https:\/\/www.unmc.edu\/newsroom\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.unmc.edu\/newsroom\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.unmc.edu\/newsroom\/#organization","name":"University of Nebraska Medical Center","url":"https:\/\/www.unmc.edu\/newsroom\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.unmc.edu\/newsroom\/#\/schema\/logo\/image\/","url":"https:\/\/www.unmc.edu\/newsroom\/wp-content\/uploads\/2022\/08\/overview-1.png","contentUrl":"https:\/\/www.unmc.edu\/newsroom\/wp-content\/uploads\/2022\/08\/overview-1.png","width":500,"height":153,"caption":"University of Nebraska Medical Center"},"image":{"@id":"https:\/\/www.unmc.edu\/newsroom\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/unmcedu","https:\/\/x.com\/unmc","https:\/\/instagram.com\/iamunmc","https:\/\/www.youtube.com\/user\/UNMCEDU"]},{"@type":"Person","@id":"https:\/\/www.unmc.edu\/newsroom\/#\/schema\/person\/64f8bde080ce4f3e8d0f0663db14e4bc","name":"Maria Daniels","url":"https:\/\/www.unmc.edu\/newsroom\/author\/202cb962ac59075b964b07152d234b70\/"}]}},"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/posts\/63562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/comments?post=63562"}],"version-history":[{"count":0,"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/posts\/63562\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/media?parent=63562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/categories?post=63562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/tags?post=63562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}